Charles River Laboratories International Inc CRL:NYSE

Last Price$129.84NYSE Previous Close - Last Trade as of 6:30PM ET 8/16/19

Today's Change+2.21(1.73%)
Bid (Size)N/A (N/A)
Ask (Size)$131.00 (2)
Day Low / High$128.77 - 130.44
Volume144.6 K

View Miscellaneous Commercial Services IndustryPeer Comparison as of 08/16/2019


Charles River Laboratories International Inc ( NYSE )

Price: $129.84
Change: +2.21 (1.73%)
Volume: 144.6 K
6:30PM ET 8/16/2019

Etsy Inc ( NASDAQ )

Price: $52.61
Change: +0.90 (1.74%)
Volume: 501.00
3:59PM ET 8/16/2019

PRA Health Sciences Inc ( NASDAQ )

Price: $96.97
Change: +2.39 (2.53%)
Volume: 361.3 K
4:00PM ET 8/16/2019

Grand Canyon Education Inc ( NASDAQ )

Price: $127.66
Change: +0.21 (0.16%)
Volume: 144.3 K
3:59PM ET 8/16/2019

Adaptive Biotechnologies Corp ( NASDAQ )

Price: $46.10
Change: -1.71 (3.58%)
Volume: 607.8 K
4:00PM ET 8/16/2019

Read more news Recent News

Charles River Labs International's Q3 and Full Year Earnings Estimates Projected Higher
1:56AM ET 8/02/2019 MT Newswires

Q3 and 2019 forecasted earnings estimate for Charles River Labs International Inc (NYSE:CRL, Recent Price: 133.91) for the quarter ending September 30,...

Charles River Laboratories Tops Street on Q2 EPS, Misses on Revenue; Increases Adjusted EPS Guidance
8:27AM ET 7/31/2019 MT Newswires

Charles River Laboratories (CRL), a pharmaceutical product supplier, reported fiscal Q2 adjusted earnings of $1.63 per share, up from $1.45 in the same...

Insider Trends: Insider Disposition Eases Back 90-Day Buy Trend at Charles River Labs
8:59AM ET 5/30/2019 MT Newswires

William D Barbo, Corporate Executive VP & CCO, sold 1,253 shares of Charles River Labs (CRL) on May 29, 2019, for $157,830. Subsequent to the Form 4...

Consensus for Charles River Labs 2019, and 2020 Earnings Reduced but Q2 Earnings Increased
1:11AM ET 5/09/2019 MT Newswires

Q2, 2019, and 2020`s earnings targets for Charles River Labs (NYSE:CRL, Recent Price: 136.28) have been revised. The Q2 earnings estimate has been raised...

Company Profile

Business DescriptionCharles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions. It operates through the following segments: Research Models & Services, Discovery & Safety Assessment, and Manufacturing Support. The Research Models & Services segment comprises of the production and sale of research models, and also offers services designed to support its client's use of research models in screening non-clinical drug candidates. The Discovery & Safety Assessment segment offers discovery and safety assessment services, both regulated and non-regulated, in which it include both in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. The Manufacturing Support segment provides endotoxin and microbial detection, avian vaccine and biologics testing solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA. View company web site for more details
Address251 Ballardvale Street
Wilmington, Massachusetts 01887
Number of Employees14,700
Recent SEC Filing08/13/20194
Chairman, President & Chief Executive OfficerJames C. Foster
Chief Financial Officer & Executive Vice PresidentDavid Ross Smith
Chief Information OfficerShanna L. Cotti-Osmanski
Senior VP-Regulatory Affairs & ComplianceBarbara j. Patterson

Company Highlights

Price Open$128.77
Previous Close$129.84
52 Week Range$103.00 - 149.07
Market Capitalization$6.3 B
Shares Outstanding48.8 M
SectorCommercial Services
IndustryMiscellaneous Commercial Services
Next Earnings Announcement11/06/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings29.38
Earnings per Share$4.79
Beta vs. S&P 500N/A
Revenue$2.3 B
Net Profit Margin8.94%
Return on Equity16.14%

Analyst Ratings as of 08/09/2019

Consensus RecommendationConsensus Icon
Powered by Factset